Translational Research


Buesing Lab

Dr. Buesing and her research team focus their investigations on lung pathology secondary to inhalation injury and potential novel therapeutic strategies. Dr. Buesing’s interest in the deleterious effects of isolated smoke inhalation originated from her prior experience as an EMT and Firefighter, and has since expanded to include countermeasures targeted to inhalational bioterrorism agents through her work with the National Strategic Research Institute (NSRI) and DoD contracting agencies.

Since 2014, Dr. Buesing and her team have collaborated in a multi-institution, multi-disciplinary investigation of acute lung injury and novel treatment strategies to bypass the failing pulmonary system.  Dr. Buesing has led this effort through three Department of Defense-sponsored contracts studying the efficacy of oxygen microbubbles (OMBs) for severe hypoxia. Utilizing body cavities such as the abdomen and intestine, Dr. Buesing and her team have shown that OMB therapy augments systemic oxygen levels independent of the lungs. Currently, OMB therapy is poised to undergo pre-clinical safety testing in humans and eventual Phase I FDA trials. 


Dr. Buesing in the news:

University of Nebraska: Making an Impact

Helping Patients with Lung Injuries | Omaha World Herald

DoD Awards NSRI Collaboration $3.7 Million | UNMC News

Rectal Breathing: Ventilation Alternative | New Scientist


Key Publications: